Consistent to the previous studies assessing glycemic control in patients with T2DM after initiation of insulin therapy [25,26,36–39], the current result showed that a lower proportion of patients achieved target FPG level during the 1-year follow-up period. This evidence concerns the gene INS and type 2 diabetes mellitus.